✦ LIBER ✦

Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500

✍ Scribed by Glen J. Weiss, Ross C. Donehower, Tara Iyengar, Ramesh K. Ramanathan, Karen Lewandowski, Eric Westin, Karla Hurt, Scott M. Hynes, Stephen P. Anthony, Scott McKane

Book ID: 118299107
Publisher: Springer US
Year: 2012
Tongue: English
Weight: 275 KB
Volume: 31
Category: Article
ISSN: 0167-6997
DOI: 10.1007/s10637-012-9815-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

516 A phase 1 dose-escalation study to e

516 A phase 1 dose-escalation study to examine the safety and tolerability of LY2603618 administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer

✍ G. Weiss; R. Donehower; E. Westin; A. Bence; S. Hynes; K. Hurt 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 45 KB

A phase 1 open-label, sequential dose-es

A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors

✍ Ghamande, Sharad; Lin, Chia-Chi; Cho, Daniel C.; Shapiro, Geoffrey I.; Kwak, Eun 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 318 KB

97 POSTER A phase I dose-escalation stud

97 POSTER A phase I dose-escalation study of the safety and pharmacokinetics of a novel spectrum selective kinase inhibitor, XL820, administered orally to patients with solid tumors

✍ K. Papadopoulos; J. Rodon; A. Mita; P. O'Rourke; A. Patnaik; E. Rubin; A. Tolche 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 59 KB

405 POSTER A phase I dose-escalation stu

405 POSTER A phase I dose-escalation study of the safety and pharmacokinetics of a XL184, a VEGFR and Met kinase inhibitor, administered orally to subjects with advanced malignancies

✍ R. Kurzrock; L. Camacho; D. Hong; C. Ng; L. Janisch; M.J. Ratain; R. Salgia 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 90 KB

A Phase 1 dose-escalation study of the s

A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors

✍ Shapiro, Geoffrey I.; McCallum, Stewart; Adams, Laurel M.; Sherman, Laurie; Well 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 260 KB

27 ORAL Phase I dose escalation study of

27 ORAL Phase I dose escalation study of the aurora kinase inhibitor PHA-739358 administered as a 6-hour infusion on days 1, 8 and 15 every 4 weeks in patients with advanced/metastatic solid tumors

✍ M. De Jonge; N. Steeghs; J. Verweij; J.W.R. Nortier; F. Eskens; J. Ouwerkerk; C. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 82 KB